Clinical Trials Logo

Clinical Trial Summary

This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04853498
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status Recruiting
Phase Phase 1
Start date April 30, 2021
Completion date May 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC Phase 2
Recruiting NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase 1/Phase 2
Recruiting NCT03230734 - Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Phase 2
Active, not recruiting NCT03732820 - Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Phase 3
Recruiting NCT04068896 - Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Phase 1
Recruiting NCT04509557 - [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. Phase 1
Recruiting NCT04227275 - A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Recruiting NCT02744287 - Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT02861573 - Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Phase 1/Phase 2
Recruiting NCT03176381 - Tissue Predictors of Abiraterone Benefit
Completed NCT02111577 - Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer Phase 3
Completed NCT02116582 - A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer Phase 4
Active, not recruiting NCT02044354 - Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer Phase 3
Completed NCT02705469 - A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1
Recruiting NCT04586543 - Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma Phase 2
Recruiting NCT04703920 - Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Phase 1
Active, not recruiting NCT01517802 - A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Phase 3
Not yet recruiting NCT04740034 - A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma Phase 1
Completed NCT02091531 - Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients Phase 2